A413 questionnaire regarding their medical care and self management. Medications (within the last 7 days), physical examination and laboratory tests were documented. DDMP participation was validated by the primary physician. Only DM2s with statutory health insurance and validated DDMP enrolment were included in the analysis (n 166). Regression analyses adjusting for confounders (age, sex, education, diabetes duration and previous diabetes complications) were conducted. RESULTS: DDMP enrolees (n 89) reported medical examination of eyes and feet and medical advice regarding diet and physical activity more frequently (p 0.005), received antidiabetic and antihypertensive medications more often (p 0.05) and attended diabetes education more frequently (p 0.005). DDMP enrolees measured their blood pressure more frequently (p 0.05). The groups did not differ regarding Hemoglobin A1c (HbA1c), but of 54 DM2s with values over 7%, only 3.6% of DDMP enrolees were receiving no antihyperglycemic medication whereas this was true for 38.5% of those not in DDMP. This difference remained significant (p 0.0129) after adjustment for diabetes duration. CONCLUSIONS: According to our study, health care quality in DDMPs is improved. However, patient self-management of all diabetics must be improved.
1
Kendle GmbH, Munich, Germany, 2 Sanofi-Aventis, Berlin, Germany, 3 Universität Erlangen-Nürnberg, Nürnberg, Germany OBJECTIVES: Suboptimal compliance and failure to persist with antidiabetes therapies are of potential economic significance. The present research aims to review the recent literature regarding the impact of poor compliance and persistence with antidiabetes medications on the cost of health care or its components for patients with type 2 diabetes mellitus (T2DM). METHODS: Systematic literature search was conducted in pubmed for relevant articles published in the period between January 1, 2000 and April 30, 2009 . Studies describing economic consequence of compliance and/or persistence with pharmaceutical antidiabetes treatment were identified. RESULTS: Of 449 articles corresponding to the primary search algorithm, 12 studies (all conducted in USA) fulfilled inclusion criteria regarding the economic impact of compliance and/or persistence with treatment on the overall cost of T2DM care or its components. Compliance was assessed via medication possession ratio (MPR) in 10 studies, and ranged from 0.52 to 0.93 depending on regimen. Persistence was assessed in one study. Mean total annual costs per patient having T2DM varied between the studies, ranging from $4,570 to $17,338. In 7 studies medication compliance was inversely associated with total health care costs, while in four other studies inverse associations between medication compliance and hospitalisation costs were reported. In one study increased adherence did not change overall health care costs. CONCLUSIONS: Improved compliance can lead to reductions of the total health care costs in T2DM, mainly through decrease in hospitalisations. Studies assessing economic impact of persistence with pharmacotherapy in T2DM are limited, and studies investigating cost consequences of compliance are predominantly using MPR as a measure of compliance. Further research is needed in countries other than USA to assess impact of compliance and persistence to pharmacotherapy on T2DM costs in country-specific settings. Researchers should follow definitions of compliance and persistence proposed by the ISPOR Medication Compliance and Persistence Special Interest Group.
PDB63 THE UTILIZATION OF ROSIGLITAZONE AND PIOGLITAZONE AFTER THE CARDIOVASCULAR RISK-WARNINGS: WAS THERE A DIFFERENTIAL EFFECT?
Jain R 1 , Mullins CD 2 , Lee H 3 , Wong W 3 1 University of Georgia, Athens, , GA, USA, 2 University of Maryland, Baltimore, MD, USA, 3 CareFirst BlueCross BlueShield, Baltimore, MD, USA OBJECTIVES: Meta-Analyses of oral hypoglycemic agents (OHA) revealed that Rosiglitazone (Rosi) increased the risk of Myocardial Infarction (MI) and Heart Failure (HF), and Pioglitazone (Pio) increased the risk of HF and decreased the risk of MI. The objective of this research is to compare OHA utilization patterns, before and after these publications. METHODS: CareFirst BlueCross BlueShield's claims were analyzed for patients continuously enrolled from January 2005 through December 2007 who started on mono-Rosi or mono-Pio. The "pre-publication" period (November 1, 2006 -March 31, 2007 ) was compared to the "post-publication" period (July 1, 2007-December 1, 2007) using a difference-in-difference approach. Multinomial logistic regression (MLR) explored discontinuation; continuation with monotherapy or adding another drug; and switching after adjusting for gender, age, type of insurance, history of MI or HF and risk factors for MI and HF. RESULTS: The number of monotherapy Rosi users decreased from the pre (N 368, 5.94%) to post (N 170, 2.87%) period, while monotherapy Pio use was stable across the two periods. The proportion who switched from Rosi to non-Rosi drugs changed from 2.17% in pre-period to 5.88% in post period. Adjusted relative risk was 2.66 (95 % CI 1.0569, 6.7689). Pio to non-pio drugs switching was 1.48% in pre-period and 1.16% in postperiod (relative risk not significant). Therefore, the impact of the new studies on Rosi users to switch to non-Rosi drug, relative to Pio users before and after the publication was 3.6189 (90%CI 1.051, 12.457). CONCLUSIONS: Consistent with prior research, the utilization of Rosi declined by more than half in the post-period. Additionally, Rosi users were three times more likely to switch to a non-Rosi drug in the post period, relative to Pio users. Therefore, our results show that the publications about safety risks had differential impact between the two drugs within therapeutic class. Following a commitment to an intensive glucose-lowering regimen that includes mealtime insulin is eventually required by patients taking basal insulin to maintain good glycemic control. The objective of this study was to characterize and examine factors associated with persistence to mealtime insulin. METHODS: Patients with diagnosed type-2 diabetes, with at least 2 prescriptions for mealtime insulin (index medication) between July 2001 and Sept 2006, were identified from a US managed care claims database. Patients were required to have 6 months pre-and 15 months post-index continuous eligibility and at least 2 basal insulin prescriptions in pre-index period. Persistence measure #1 was defined by the absence of prescription gap of greater than 90 days, with non-persistence effective the date of the last prescription prior to the 90 day gap. Persistence measure #2 required one prescription per quarter to be persistent at 12 months; persistence at 3 and 6 months were defined similarly. Logistic regression models were used to examine predictors of persistence to mealtime insulin at 12 months. RESULTS: Patients adding mealtime insulin to their basal regimen (n 4,752; 51% male, mean age 60.3 years) mostly used insulin analogs (60%) and vial/syringe (87%). The median number of mealtime insulin prescription claims filled per patient was 2, 3 and 4 at 3, 6 and 12 months respectively, with the median time between refills being 75.5 days. Persistence to mealtime insulin was 40.7%, 30.2% and 19.1% using measure #1 and 74.3%, 55.3% and 42.2% using measure # 2 at 3, 6 and 12 months, respectively. Patients initiating with human insulin were less likely to be persistent across measures of persistence (OR 0.80, p 0.01). Additional predictors of persistence at 12 months included age, copayment, mental health comorbidity and polypharmacy. CONCLUSIONS: Persistence to insulin therapy is poorer than one would anticipate and is significantly lower for human insulin compared to analogs.
PDB64 A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME INSULIN TO A BASAL REGIMEN

PDB65
REAL-LIFE PRESCRIPTION PATTERNS SHOW FEWER TREATMENT CHANGES WITH BASAL INSULIN ANALOGS COMPARED TO NPH IN TYPE 2 DIABETES IN THE NETHERLANDS
Thomsen TL 1 , Heintjes EM 2 , Penning-van Beest FJA 2 , Christensen TE 1 , Herings RM 2 1 Novo Nordisk A/S, Virum, Denmark, 2 PHARMO Institute, Utrecht, The Netherlands OBJECTIVES: Using the Dutch PHARMO database, the aim was to 1) determine the percentage of type 2 diabetes (T2D) patients starting on long-acting insulin analogues versus NPH; 2) compare previous insulin experience in patients; and 3) establish the number of patients changing treatment within one year. METHODS: The PHARMO database includes community pharmacy drug dispensing and hospitalisation records from approximately 2.5 million patients. Data was extracted for insulin naïve and prior insulin T2D patients initiated on basal insulin as monotherapy or as part of a basal-bolus regimen in [2004] [2005] [2006] . RESULTS: The study included 7209 new basal insulin users, of which 4792 (67%) were insulin naive. Overall, 4728 (66%) used analogues, with similar proportions using monotherapy (67%) and basal-bolus therapy (65%). The proportion of analogue users was greater among prior insulin users: 541 of 619 (87%) for monotherapy and 1331 of 1798 (74%) for basal-bolus therapy compared with 2258 of 3702 (61%) and 598 of 1090 (55%) among naïve users. Monotherapy for naïve patients was initiated mainly by the GP (NPH 70%, analogue 59%), for prior users mainly by the internist (NPH 49%, analogue 59%)%), same as for basal-bolus users (NPH 67-68%, analogue 75-80%). With NPH, 22% discontinued their prescription (average of 220 days) and with basal analogues 17% (average of 230 days). Furthermore, 6% of patients on NPH and 11% with basal analogues added-on to their prescription (after an average of 119 days and 126 days, respectively). Only 17% of patients switched treatment with basal analogues compared with NPH (average of 190 days) versus 32% (average of 158 days), respectively. CONCLUSIONS: When new insulin treatment is initiated, analogues are more often prescribed than NPH, more frequently prescribed by Dutch internists and not discontinued or switched as frequently as NPH, indicating that basal insulin analogues give a more sustained and satisfactory result.
PDB66 PAYING FOR COSTLY PHARMACEUTICALS-REIMBURSEMENT STATUS OF LONG-ACTING INSULIN ANALOGUES IN SELECTED DEVELOPED COUNTRIES
Orlewska E 1 , Gulácsi L 2 1 Centrum Farmakoekonomiki, Warsaw, Poland, 2 Corvinus University of Budapest, Budapest, Hungary OBJECTIVES: Many aspects of the scientific, economic and political discussions on the benefit of new medicines, for which modern insulins are a pivotal example, influence recent decisions about drug reimbursement. This study was undertaken to compare the reimbursement status of long acting insulin analogues (LAIA) in several industrialized countries around the globe, where different criteria for public funding of pharmaceuticals have been used, but all include estimates of clinical effectiveness and/or cost effectiveness. METHODS: The study was performed based on a combination of desk research, direct contact with national diabetes stakeholders and expert review, using a pre-defined questionnaire. In the first phase, information was gathered from each country on diabetes prevalence, cost, relevant policies and guidelines through a range of sources including government and patient association websites, published scientific literature, media reports. In the second phase additional information about reimbursement status of LAIA was sought from recommendations obtained from the websites of HTA or similar agencies, or interviews carried out with national stakeholders representing health ministries, patient organisations or medical community. RESULTS: Fifteen countries have been included in the study (Australia, New Zealand, Canada, UK, The Netherlands, France, Germany, Austria, Sweden, Norway, Latvia. Lithuania, Estonia, Hungary, Bulgaria). Only in France LAIA are reimbursed in 65%, in all remained countries-in 100%. But in most countries there are several restrictions on access to LAIA, namely criteria for this type of treatment have been developed to respond the clinical and economic evidence (use in selected patients, application only from a relevant specialist, regular reassessments of metabolic control, listing after the company agreed to a price reduction). CONCLUSIONS: The story of LAIA is important not only because of the way the evidence has been interpreted, but because the voice of consultative bodies resulted in action by the health care purchasers.
PDB67 HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC
Tesar T, Foltan V, Binder R Comenius University, Bratislava, Slovak Republic OBJECTIVES: The aim of this study was to collect comparable and reliable data about consumption of drugs for treatment of diabetes mellitus in Slovakia during the period 1999-2008. METHODS: Data of wholesalers (following ATC/DDD), who are legally obliged provide this information to the Slovak Institute for Drug Control, was used for the analysis. The results were expressed in the numbers of the packages, finance units (a) and defined daily doses per 1000 inhabitants per day (DID). RESULTS: The collected data shows a significant increases in the antidiabetic's consumption from 1999 to 2008 in term of DID (in 1999 (33.34) (17.57), in 2003 (15.87) and in 2008 (19.29 ) and a moderate increase in A10BD (Biguanides and sulfonamides in combination) in 1999 (0.52), in 2003 (0.95) and in 2008 (1.68) in term of DID can be seen from this analysis. Financial expenditures for antidiabetics were in 1999 (a19,271,000) and in 2008 (a38,952,000). CONCLU-SIONS: Inseparable components of the Slovak drug policy must be viewed realistically with regard to the antidiabetics' consumption. Adherence to principles of diabetes mellitus treatment's guidelines lead to fundamental short and long term financial savings within health care systems.
